ES2249762T3
(es)
|
1994-03-08 |
2006-04-01 |
Human Genome Sciences, Inc. |
Factor de crecimiento del endotelio vascular 2.
|
US6608182B1
(en)
*
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
US7186688B1
(en)
|
1994-03-08 |
2007-03-06 |
Human Genome Sciences, Inc. |
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
|
US6734285B2
(en)
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7109308B1
(en)
*
|
1994-03-08 |
2006-09-19 |
Human Genome Sciences, Inc. |
Antibodies to human vascular endothelial growth factor 2
|
US6040157A
(en)
*
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7153827B1
(en)
|
1994-03-08 |
2006-12-26 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 and methods of use
|
US5928939A
(en)
*
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
US7160991B1
(en)
|
1995-03-02 |
2007-01-09 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor polypeptides
|
CA2214439C
(en)
*
|
1995-03-02 |
2002-12-17 |
Amrad Operations Pty. Ltd. |
A novel growth factor and a genetic sequence encoding same
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
EP0873348A4
(en)
*
|
1995-06-06 |
2000-11-08 |
Human Genome Sciences Inc |
GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM
|
US7727761B2
(en)
*
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
WO1997009427A1
(en)
|
1995-09-08 |
1997-03-13 |
Genentech, Inc. |
Vegf-related protein
|
WO1997012972A2
(en)
|
1995-09-29 |
1997-04-10 |
Universita'degli Studi Di Siena |
Regulated genes and uses thereof
|
WO1997017442A1
(en)
|
1995-11-08 |
1997-05-15 |
Immunex Corporation |
Flk-1 binding protein
|
US6994989B1
(en)
|
1995-11-08 |
2006-02-07 |
Immunex Corp. |
FLK-1 binding proteins
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
CA2263890C
(en)
|
1996-08-23 |
2013-05-14 |
Ludwig Institute For Cancer Research |
Recombinant vascular endothelial cell growth factor d (vegf-d)
|
WO1998024811A2
(en)
*
|
1996-12-06 |
1998-06-11 |
Zymogenetics, Inc. |
Vascular endothelial growth factor
|
AU742779B2
(en)
*
|
1996-12-20 |
2002-01-10 |
Licentia Oy |
VEGF-B/receptor complex and uses thereof
|
AU6691098A
(en)
|
1997-03-07 |
1998-09-22 |
Wistar Institute Of Anatomy & Biology, The |
Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
|
CN1260835A
(zh)
*
|
1997-04-25 |
2000-07-19 |
科莱特诺医疗公司 |
截短的vegf相关蛋白质
|
US6281175B1
(en)
|
1997-09-23 |
2001-08-28 |
Scimed Life Systems, Inc. |
Medical emulsion for lubrication and delivery of drugs
|
AU767662B2
(en)
|
1998-02-06 |
2003-11-20 |
Collateral Therapeutics, Inc. |
Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
|
US20030118567A1
(en)
*
|
1999-03-26 |
2003-06-26 |
Stewart Duncan John |
Cell-based therapy for the pulmonary system
|
DE19813774A1
(de)
*
|
1998-03-27 |
1999-09-30 |
Max Planck Gesellschaft |
Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
|
EP1129110B1
(en)
|
1998-11-10 |
2009-12-09 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor d, dna coding therefor, and uses thereof
|
US6783953B1
(en)
|
1998-12-22 |
2004-08-31 |
Janssen Pharmaceutica N.V. |
Vascular endothelial growth factor-X
|
AU3693000A
(en)
*
|
1999-01-29 |
2000-08-18 |
Licentia Ltd |
Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
AU3614700A
(en)
*
|
1999-03-03 |
2000-09-21 |
Ludwig Institute For Cancer Research |
Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
|
WO2000064261A1
(en)
*
|
1999-04-26 |
2000-11-02 |
Ludwig Institute For Cancer Research |
Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
|
WO2000075329A1
(en)
*
|
1999-06-07 |
2000-12-14 |
Edwards Lifesciences Corporation |
Targeted angiogenesis
|
US8188043B2
(en)
*
|
1999-07-28 |
2012-05-29 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Nicotine in therapeutic angiogenesis and vasculogenesis
|
DE60040293D1
(de)
*
|
1999-07-28 |
2008-10-30 |
Univ R |
Verwendung von nikotin in der angiogenese und der vaskulogenese
|
DE60136334D1
(en)
*
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
AUPQ568100A0
(en)
*
|
2000-02-16 |
2000-03-09 |
Amrad Operations Pty. Limited |
A method for producing recombinant molecules
|
AU2001239884B2
(en)
*
|
2000-02-25 |
2006-08-10 |
Vegenics Limited |
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
US20030104977A1
(en)
*
|
2000-03-31 |
2003-06-05 |
Ugo Ripamonti |
Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
|
CA2405701A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001261705A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Ludwig Institute For Cancer Research |
Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
|
EP1303594A4
(en)
*
|
2000-07-26 |
2004-07-14 |
Ludwig Inst Cancer Res |
GLYCOSYLATED VEGF-B AND METHOD FOR INCREASING THE QUANTITY OF SOLUBLE VEGF-B
|
CN1211126C
(zh)
*
|
2000-08-04 |
2005-07-20 |
人体基因组科学有限公司 |
血管内皮生长因子2
|
US20020151489A1
(en)
*
|
2000-10-02 |
2002-10-17 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
AU2002224471A1
(en)
*
|
2000-11-01 |
2002-05-15 |
Aventis Pharma S.A. |
In vivo stimulation of angiogenic activity
|
US7067317B2
(en)
*
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7026462B2
(en)
*
|
2000-12-07 |
2006-04-11 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
US20070111944A1
(en)
*
|
2001-02-16 |
2007-05-17 |
Scrofani Sergio D B |
Purification of vascular endothelial growth factor-B
|
US20070050857A1
(en)
*
|
2001-02-28 |
2007-03-01 |
Hayward Nick K |
Method of treatment and prophylaxis
|
AU2002303261A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
US7402312B2
(en)
*
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
CA2444624A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
WO2002083850A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
DK1407276T3
(da)
*
|
2001-04-24 |
2009-12-21 |
Vlaams Interuniv Inst Biotech |
Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom
|
WO2003000009A2
(en)
*
|
2001-06-20 |
2003-01-03 |
Ludwig Institute For Cancer Research |
Stimulation of vascularization with vegf-b
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
AU2002319402B2
(en)
*
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
JP2005500045A
(ja)
*
|
2001-07-12 |
2005-01-06 |
ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ |
リンパ管内皮細胞材料および方法
|
US7217570B2
(en)
|
2001-08-23 |
2007-05-15 |
The Wistar Institute Of Anatomy And Biology |
Organotypic intestinal culture and methods of use thereof
|
US20030113324A1
(en)
*
|
2001-10-01 |
2003-06-19 |
Kari Alitalo |
Neuropilin/VEGF-C/VEGFR-3 materials and methods
|
US20040214766A1
(en)
*
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030221931A1
(en)
|
2002-02-28 |
2003-12-04 |
Steve Marsh |
Sliding device
|
US20040005671A1
(en)
*
|
2002-05-17 |
2004-01-08 |
Amrad Operations Pty Ltd. |
Immunointeractive molecules
|
EP1912069A3
(en)
|
2002-06-05 |
2008-07-09 |
Sopherion Therapeutics, Inc. |
Method to screen ligands using eukaryotic cell display
|
US20030235864A1
(en)
*
|
2002-06-05 |
2003-12-25 |
Sopherion Therapeutics, Inc. |
Method to screen ligands using eukaryotic cell display
|
US20030232439A1
(en)
*
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-B expression
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
EP2366718A3
(en)
*
|
2002-06-28 |
2012-05-02 |
Domantis Limited |
Ligand
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
CA2493572A1
(en)
|
2002-07-23 |
2004-01-29 |
Ludwig Institute For Cancer Research |
Methods and compositions for activating or inhibiting vegf-d and vegf-c
|
US7470538B2
(en)
*
|
2002-12-05 |
2008-12-30 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
US20040258670A1
(en)
*
|
2002-12-05 |
2004-12-23 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
JP2006523090A
(ja)
*
|
2002-12-27 |
2006-10-12 |
ドマンティス リミテッド |
リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
|
AU2004209668A1
(en)
*
|
2003-02-04 |
2004-08-19 |
Flanders Interuniversity Institute For Biotechnology |
VEGF-B and PDGF modulation of stem cells
|
US7759472B2
(en)
|
2003-08-27 |
2010-07-20 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
EP1560025A3
(en)
*
|
2003-10-03 |
2011-09-07 |
F. Hoffmann-La Roche AG |
Specific markers for diabetes
|
WO2005067889A1
(en)
|
2003-12-30 |
2005-07-28 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
|
WO2005084329A2
(en)
*
|
2004-03-02 |
2005-09-15 |
Ludwig Institute For Cancer Research |
Method for inhibiting tumor formation and growth
|
US20060024302A1
(en)
*
|
2004-03-05 |
2006-02-02 |
Ludwig Institute For Cancer Research |
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
|
US20050282233A1
(en)
*
|
2004-03-05 |
2005-12-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
|
AU2005232665B2
(en)
*
|
2004-04-08 |
2010-05-13 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
DK1781321T3
(da)
*
|
2004-08-02 |
2014-04-14 |
Zenyth Operations Pty Ltd |
Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
|
US7595149B1
(en)
|
2004-11-08 |
2009-09-29 |
University Of Kentucky Research Foundation |
Methods for cancer detection
|
JP4988606B2
(ja)
*
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
抗血管新生方法及び組成物
|
CN101277704A
(zh)
*
|
2005-04-12 |
2008-10-01 |
因特拉迪格姆公司 |
用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
|
US7893244B2
(en)
*
|
2005-04-12 |
2011-02-22 |
Intradigm Corporation |
Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
|
ATE502956T1
(de)
|
2005-08-15 |
2011-04-15 |
Vegenics Pty Ltd |
Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
|
KR20080077238A
(ko)
*
|
2005-12-01 |
2008-08-21 |
도만티스 리미티드 |
인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
|
AU2007254243B2
(en)
|
2006-05-17 |
2013-06-13 |
Ludwig Institute For Cancer Research |
Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
|
WO2008085229A2
(en)
*
|
2006-11-15 |
2008-07-17 |
Arteriocyte Inc. |
Cell-based therapies for treating liver disease
|
BRPI0812398A2
(pt)
*
|
2007-06-06 |
2019-09-24 |
Domantis Ltd |
domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
|
US7819579B2
(en)
*
|
2007-11-26 |
2010-10-26 |
Schmulenson Harold K |
Radiation sensing device and holder
|
WO2009075565A1
(en)
*
|
2007-12-12 |
2009-06-18 |
Erasmus University Medical Center Rotterdam |
Methods for controlling vasculogenesis
|
CA2710680C
(en)
|
2007-12-26 |
2018-10-16 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
US20110150900A1
(en)
*
|
2008-04-09 |
2011-06-23 |
Ludwig Institute For Cancer Research |
Regulation of fatty acid transporters
|
IL205774A0
(en)
*
|
2010-05-13 |
2010-12-30 |
Muhammad Abdulrazik |
Novel compounds for the treatment of glaucoma and ocular hypertension
|
KR101335203B1
(ko)
*
|
2010-03-26 |
2013-11-29 |
숙명여자대학교산학협력단 |
혈관신생촉진용 펩타이드 및 이의 용도
|
WO2011154308A1
(en)
|
2010-06-08 |
2011-12-15 |
Proyecto De Biomedicina Cima, S.L. |
New compositions and cell therapy methods for the treatment of cirrhosis
|
RU2477529C2
(ru)
*
|
2011-04-28 |
2013-03-10 |
Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" |
Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
|
BR112016000546A2
(pt)
|
2013-07-12 |
2017-11-21 |
Ophthotech Corp |
métodos para tratar ou prevenir condições oftalmológicas
|
CN105979965B
(zh)
*
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
CN107661492A
(zh)
*
|
2017-08-31 |
2018-02-06 |
中山大学中山眼科中心 |
Vegf‑b的新用途
|
CN107537026A
(zh)
*
|
2017-08-31 |
2018-01-05 |
中山大学中山眼科中心 |
Vegf‑b的应用
|
US10745454B2
(en)
*
|
2018-01-31 |
2020-08-18 |
Seyed Mohsen Asghari |
Method of synthesizing antagonist peptides for cell growth
|
CN109337931A
(zh)
*
|
2018-11-02 |
2019-02-15 |
东北师范大学 |
Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
|
CN110777146A
(zh)
*
|
2019-11-28 |
2020-02-11 |
南通大学 |
一种pdgfb启动子活性报告质粒的构建方法
|